Today: 20 May 2026
Ondas stock jumps again as analysts lift targets, even as tariff jitters rattle markets
21 January 2026
2 mins read

Ondas stock jumps again as analysts lift targets, even as tariff jitters rattle markets

NEW YORK, January 21, 2026, 10:42 EST

  • Ondas shares climbed roughly 4% in mid-morning trading following a series of upbeat analyst reports.
  • After the company raised its 2026 revenue outlook and revealed a surge in backlog, Wall Street firms pushed up their price targets.
  • The moves follow the biggest single-day drop for U.S. stocks in three months, sparked by fresh tariff concerns.

Shares of Ondas Inc rose once more on Wednesday, gaining roughly 4% to hit $13.64 during mid-morning trading in New York. The uptick extends a volatile streak that’s drawn additional Wall Street analysts to the stock.

The latest upgrades come at a tricky time for risk appetite. Investors are still working through a broad selloff sparked by new tariff threats, yet they’re also hunting for stocks showing their own momentum — contract wins, updated guidance, anything to cut through the macro noise.

On Tuesday, the S&P 500 dropped 2.06% to 6,796.86, while the Nasdaq Composite slid 2.39% to 22,954.32 and the Dow fell 1.76% to 48,488.59, Reuters reported. The selloff came after President Donald Trump’s weekend remarks about imposing a 10% import tariff starting Feb. 1 on goods from several European countries, with plans to hike that to 25% on June 1 unless the U.S. strikes a deal to buy Greenland. “I’m not at the point yet” where the tariff dispute will spark a broader equity correction, Jamie Cox, managing partner at Harris Financial Group, told Reuters. Reuters

Ondas has been moving on analyst forecasts rather than market action. Timothy Horan at Oppenheimer stuck with an outperform rating, raising his price target to $16 from $12. Needham’s Austin Bohlig also bumped his target, this time to $17 from $12, according to a Benzinga report shared by Finviz. Amit Dayal of H.C. Wainwright & Co held onto a buy rating and pushed his target up sharply to $25 from $12.

Analysts linked the stock moves to revised guidance and clearer visibility ahead. Ondas upped its 2026 revenue forecast to between $170 million and $180 million, up from $140 million, and projected fourth-quarter 2025 revenue of $27 million to $29 million, according to InvestorsObserver. The company’s backlog — orders secured but undelivered — stood at $65.3 million as of Dec. 31, a sharp 180% rise since Nov. 13, the report noted. In a client update, Dayal’s team said Ondas is “entering 2026 from a position of strength,” highlighting gains in autonomous aerial and robotics sectors. Investorsobserver

Other small-cap drone stocks edged higher Wednesday. Red Cat Holdings jumped close to 10%, while Draganfly added around 5% in morning trading. Investors remain drawn to the defense-drone space despite Tuesday’s surprise.

But the Ondas story isn’t without controversy. CTech, the technology division of Israel’s Calcalist, pointed out how fast the company’s valuation soared—reaching about $5 billion after a year when Ondas was actually facing delisting threats and had going-concern warnings. This spike came amid a swift spree of acquisitions of Israeli defense firms.

Wednesday’s action appeared steadier compared to Tuesday’s finish. The SPY, a major S&P 500 ETF, gained roughly 0.7%, and QQQ, tracking the Nasdaq-100, climbed about 0.9% by mid-morning.

Ondas is focusing its growth strategy on autonomous systems, including counter-drone tech called C-UAS (counter–unmanned aerial systems), plus private wireless networks aimed at industrial and government sectors. An article on Nasdaq.com this week highlighted how the company used an investor day to rebrand its autonomous unit as a wider “multi-domain” platform and raised its revenue targets for 2026. Nasdaq

Investors face a straightforward question for now: can Ondas turn its backlog and pipeline promises into audited revenue without issuing more shares? And can it manage that amid ongoing headline-driven market volatility?

Stock Market Today

  • Navitas Semiconductor Advances Toward Operating Breakeven with AI Growth
    May 20, 2026, 9:56 AM EDT. Navitas Semiconductor (NVTS) reported Q1 2026 revenues of $8.6 million, up from $7.3 million last quarter, driven by stronger demand in AI data centers, grid, and industrial applications. The company expects Q2 revenues near $10 million, marking 16% sequential growth. Adjusted gross margin rose slightly to 39%. Operating expenses are forecast stable around $14.5-$15.5 million. Navitas indicated that revenues near $30 million per quarter could support operating profitability if current margin and expense levels hold. Its AI infrastructure business grew 50% sequentially in Q1, highlighting a potential multi-billion dollar market by 2030. Peer ON Semiconductor showed strong AI data center growth and margin expansion, while Infineon reported modest revenue gains with margin pressure. Navitas' focus on high-value products and AI-driven growth may bridge the profit gap, though operating breakeven remains a future target.

Latest articles

Vida’s $15 Million AI IPO Faces Its First Reality Check as CEO Buys In

Vida’s $15 Million AI IPO Faces Its First Reality Check as CEO Buys In

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Broadcom stock price steadies after 5% drop as Trump tariffs dominate the tape — what AVGO investors watch next
Previous Story

Broadcom stock price steadies after 5% drop as Trump tariffs dominate the tape — what AVGO investors watch next

Vanguard’s VTI ETF rebounds after Trump’s Greenland tariff threat rattles U.S. stocks
Next Story

Vanguard’s VTI ETF rebounds after Trump’s Greenland tariff threat rattles U.S. stocks

Go toTop